Sugi Predict

Sugi Predict / Compounds / SCHEMBL3604233

SCHEMBL3604233

SCHEMBL3604233

CC(C)c1cccc(O)c1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 4/20 0.60
▸ GABRB2 P47870 2/20 0.60
▸ CA1 P00915 4/20 0.56
▸ CA2 P00918 4/20 0.56
▸ LMNA P02545 4/20 0.56
▸ HPGD P15428 3/20 0.56
▸ GABRG2 P18507 2/20 0.56
▸ GABRB3 P28472 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ GABRB1 P18505 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ SLC6A2 P23975 2/20 0.56
▸ HTR2B P41595 2/20 0.56
▸ FAAH O00519 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ PTGS1 P23219 1/20 0.56
▸ HTR2C P28335 1/20 0.56
▸ GABRA5 P31644 1/20 0.56
▸ GABRA3 P34903 1/20 0.56
▸ GABRA2 P47869 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31634517 1.00 GABRA1 (0.60) GABRA1GABRB2CA1CA2LMNA
SCHEMBL17226938 0.84 GABRA1 (0.46) GABRA1GABRB2CA1CA2LMNA
SCHEMBL2202295 0.83 GABRA1 (0.55) GABRA1GABRB2CA1CA2LMNA
SCHEMBL16955404 0.83 GABRA1 (0.45) GABRA1GABRB2CA1CA2LMNA
SCHEMBL10716602 0.79 LMNA (0.45) GABRA1GABRB2CA1CA2LMNA
SCHEMBL23645287 0.77 POLB (0.39) GABRA1GABRB2CA1CA2LMNA
SCHEMBL30291381 0.77 POLB (0.39) GABRA1GABRB2CA1CA2LMNA
SCHEMBL23705916 0.77 GABRA1 (0.39) GABRA1GABRB2CA1CA2LMNA
SCHEMBL28629753 0.77 TSHR (0.48) GABRA1GABRB2CA1CA2LMNA
SCHEMBL301445 0.76 GABRA1 (0.76) GABRA1GABRB2CA1CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037020-A Supported catalyst, preparation method thereof and application thereof in olefin polymerization 中国石油化工股份有限公司 2026-05-15 — — CN claimed
CN-122037020-A Supported catalyst, preparation method thereof and application thereof in olefin polymerization 中国石油化工股份有限公司 2026-05-15 — — CN disclosed
EP-4661966-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF Type6 Therapeutics, Inc. (US) 2025-12-17 — — EP disclosed
WO-2024167848-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF TYPE6 THERAPEUTICS, INC. (US) 2024-08-15 — — WO disclosed
EP-3826983-B1 USE OF SUBSTITUTED 2-THIAZOLINES AS NITRIFICATION INHIBITORS BASF SE (DE) 2024-05-15 — — EP disclosed
CN-112679635-A Preparation method of supported metallocene catalyst and catalyst prepared by same 中国石油化工股份有限公司 2021-04-20 — — CN disclosed
EP-1637527-B1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL (JP) 2013-04-17 — — EP disclosed
CN-1816536-B Cannabinoid receptor modulators TAKAEDA CHEMICAL IND LTD 2012-12-26 — — CN disclosed
US-20110178092-A1 HIV-1 Protease Inhibitors UNIVERSITY OF MARYLAND, COLLEGE PARK 2011-07-21 — — US disclosed
US-20110178092-A1 HIV-1 Protease Inhibitors UNIVERSITY OF MARYLAND, COLLEGE PARK 2011-07-21 — — US disclosed
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-23 — — US disclosed
US-7507841-B2 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-24 — — US disclosed
US-20090023800-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-01-22 — — US disclosed
US-7465815-B2 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-16 — — US disclosed
WO-2008118849-A2 HIV-1 PROTEASE INHIBITORS UNIVERSITY OF MASSACHUSETTS (US) 2008-10-02 — — WO disclosed
US-20080021087-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-01-24 — — US disclosed
US-20070099990-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 — — US disclosed
WO-2007002172-A2 HIV-1 PROTEASE INHIBITORS UNIVERSITY OF MASSACHUSETTS (US) 2007-01-04 — — WO disclosed
CN-1816536-A Cannabinoid receptor modulators TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-08-09 — — CN disclosed
EP-1637527-A1 CANNABINOID RECEPTOR MODULATOR Takeda Pharmaceutical Company Limited (JP) 2006-03-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178092-A1 HIV-1 Protease Inhibitors SERPINB1, PRSS1, TMPRSS4 GABRA1 4274/4885GABRB2 4532/4885CA1 3635/4885
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR CNR1, CNR2, GPR18 GABRA1 96/4885GABRB2 136/4885CA1 2290/4885
US-20080021087-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 GABRA1 96/4885GABRB2 136/4885CA1 2290/4885
US-20090023800-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 GABRA1 96/4885GABRB2 136/4885CA1 2290/4885
US-20070099990-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 GABRA1 96/4885GABRB2 136/4885CA1 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.